ArticleFrontiers in cell and developmental biology2021

Humanized CD30-Targeted Chimeric Antigen Receptor T Cells Exhibit Potent Preclinical Activity Against Hodgkin's Lymphoma Cells.

Jing Guo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.